--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-24-141703" form_type: "8-K" ticker: null cik: "0001505512" company_name: "Regulus Therapeutics Inc." filed_at: "2024-05-17T23:59:59+00:00" generated_at: "2026-06-01T15:25:30.858386+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares ## Summary - Amendment increases share reserve by 9.5M shares; total authorized now 18,574,542. - Vote: 32,563,555 for, 5,916,084 against, 29,301 abstentions, 3,688,130 broker non-votes. - Automatic annual increase formula changed to include shares from convertible preferred and prefunded warrants. - All 10 director nominees elected; say-on-pay approved; Ernst & Young ratified as auditor. - Non-binding say-on-pay frequency set at one year, consistent with board recommendation. ## SEC filing metadata - accession: 0001193125-24-141703 - form_type: 8-K - cik: 0001505512 - company_name: Regulus Therapeutics Inc. - filed_at: 2024-05-17T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/d829869d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-24-141703 - JSON: https://secwatch.observer/filing/0001193125-24-141703.json - Plain text: https://secwatch.observer/filing/0001193125-24-141703.txt ## Source-grounded claims - claim_id: 0d3843106d7379e0a512c22c762c28e683b41793 claim: Regulus Therapeutics Inc. shareholders approved Approval of amendment to 2019 Equity Incentive Plan to increase authorized shares by 9,500,000 and modify automatic share reserve calculation. at the 2024-05-16 meeting. evidence_excerpt: Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130 evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm - claim_id: 92453f7d2359cba16edf7b099601d7aed7459ff1 claim: Regulus Therapeutics Inc. shareholders approved Advisory vote on frequency of say-on-pay votes. Every year selected. at the 2024-05-16 meeting. evidence_excerpt: Proposal 4. The Company’s stockholders approved, on an advisory basis, every year as the preferred frequency for holding stockholder advisory votes on the compensation of the Company’s named executive officers. One year Two Years Three Years Abstentions Broker Non-Votes 38,380,997 10,261 36,660 79,471 3,688,130 evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm - claim_id: d7edb813f81f25f3b537f93d1ce140feacbf031a claim: Regulus Therapeutics Inc. shareholders approved Advisory approval of named executive officer compensation. at the 2024-05-16 meeting. evidence_excerpt: Proposal 3. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement for the Annual Meeting. Votes For Votes Against Abstentions Broker Non-Votes 38,219,586 223,139 66,215 3,688,130 evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm - claim_id: f8e0c4d3db59f4f0be2298340d404381b9ae4795 claim: Regulus Therapeutics Inc. shareholders approved Election of ten directors named in the filing. at the 2024-05-16 meeting. evidence_excerpt: Proposal 1. Election of Directors The ten persons listed below were elected as directors at the Annual Meeting, each to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. Votes For Votes Withheld Broker Non-Votes David Baltimore, Ph.D. 38,149,013 359,927 3,688,120 Kathryn J. Collier 38,157,716 351,224 3,688,120 Joseph P. Hagan 38,375,891 133,049 3,688,120 Alice S. Huang, Ph.D. 37,595,731 913,209 3,688,120 Preston Klassen, M.D. 38,147,754 361,186 3,688,120 Jake R. Nunn 38,156,266 352,674 3,688,120 Stelios Papadopoulos, Ph.D. 38,147,155 361,785 3,688,120 William Rastetter, Ph.D. 37,568,471 940,469 3,688,120 Hugh Rosen, M.D., Ph.D. 38,157,572 351,368 3,688,120 Pascale Witz, MBA, MSc 37,834,247 674,693 3,688,120 evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm - claim_id: f8f131d77a98aad87fa76ecb28273b6981b2d026 claim: Regulus Therapeutics Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024. at the 2024-05-16 meeting. evidence_excerpt: Proposal 2. The Company’s stockholders ratified the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. Votes For Votes Against Abstentions 42,040,910 152,439 3,721 evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.